Company Active LTD

Company profile

Deep Science Ventures Limited

Home

Deep Science Ventures Limited is a UK company with status active founded in 2016 based in East of England.

CRN
10314171
Founded
2016
Age
9

Overview

Legal name
DEEP SCIENCE VENTURES LIMITED
Region
East of England
Registered address
TAYLOR VINEY & MARLOW
46-54 HIGH STREET
INGATESTONE
ESSEX
UNITED KINGDOM
CM4 9DW
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Deep Science Ventures Limited
No active corporate controller recorded.

Latest accounts

Financial period: 1 Jan 2024 to 31 Dec 2024

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
-£265,988
Employees
27

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

18 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

04 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

27 Sep
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQzNzAxNjM1MWFkaXF6a2N4 | Paper/PDF filed

Published 28 Sep 2024 06:12

20 Aug
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzMjc2OTE1NmFkaXF6a2N4

Published 20 Aug 2024 15:11

05 Aug
2016

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2020
Funded years
2020, 2022, 2024
Age at first award
3 years

Projects

2024 Department for Science, Innovation & Technology Lead participant

Bind: A new venture to exploit disordered proteins as drug targets

1 Mar 2024 to 31 Jan 2025

Awarded
£98,000
Total cost £140,000

Overview: Many incurable diseases (cancer, neurodegeneration) involve intrinsically disordered proteins. Considered 'undruggabble' by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites to which drug-molecules can attach themselves. Our mission is to make disordered prote...

2024 Department for Science, Innovation & Technology Lead participant

Bind: A new venture to exploit disordered proteins as drug targets

1 Mar 2024 to 31 Jan 2025

Awarded
£70,000
Total cost £100,000

Overview: Many incurable diseases (cancer, neurodegeneration) involve intrinsically disordered proteins. Considered 'undruggabble' by the mainstream pharmaceutical industry, disordered proteins continuously change their three-dimensional shapes and lack long-lived sites to which drug-molecules can attach themselves. Our mission is to make disordered prote...

2022 Collaborative R&D Lead participant

ICURe - venture creation

1 Apr 2022 to 31 Mar 2025

Awarded
£1,500,000
Total cost £1,500,000
2022 Collaborative R&D Lead participant

ICURe - venture creation

1 Apr 2022 to 31 Mar 2023

Awarded
£1,000,000
Total cost £1,000,000
2022 Collaborative R&D Lead participant

ICURe - venture creation

1 Apr 2022 to 31 Mar 2023

Awarded
£999,991
Total cost £999,991
2020 Study

Development of clinically translatable therapies for the treatment and prevention of bacterial vaginosis

1 Feb 2020 to 31 Oct 2021

Awarded
£0
Total cost £0

This research aims to develop new therapies for the treatment of recurrent bacterial vaginosis (BV). BV is the most common vaginal infection experienced by women of childbearing age, with up to 30% of woman of this group affected by the condition. BV is caused by the overgrowth of unwanted bacteria within the vagina. The main problematic bacterium which c...

Product types

Collaborative R&D Department for Science, Innovation & Technology Study